A5061557187- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Hematological disorders and diagnostics
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- Drug-Induced Adverse Reactions
- Immunodeficiency and Autoimmune Disorders
- Advanced Proteomics Techniques and Applications
- Analytical Chemistry and Chromatography
- Pancreatic and Hepatic Oncology Research
- Metabolomics and Mass Spectrometry Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
Antwerp University Hospital
2022-2023
University of Antwerp
2022
Purpose: Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable that in healthy individuals. Recent studies demonstrated a third vaccination dose boosts these immune responses, both people and patients cancer. Because of the availability many different vaccines, have been boosted vaccine from one used for vaccination. Data on such alternative schedules are scarce. This prospective study compares...
Background: Currently, nanoliposomal irinotecan (nal-IRI) + 5-fluorouracil/folinic acid (5-FU/LV) is the only approved second-line treatment for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). However, also other chemotherapeutic regimens are used in this setting and due to lack of clear real-world data on efficacy different regimens, there no consensus optimal sequence mPDAC patients. Objectives: To provide information safe efficacious use nal-IRI 5-FU/LV...
<div>Purpose:<p>Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable that in healthy individuals. Recent studies demonstrated a third vaccination dose boosts these immune responses, both people and patients cancer. Because of the availability many different vaccines, have been boosted vaccine from one used for vaccination. Data on such alternative schedules are scarce. This prospective...
<div>Purpose:<p>Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable that in healthy individuals. Recent studies demonstrated a third vaccination dose boosts these immune responses, both people and patients cancer. Because of the availability many different vaccines, have been boosted vaccine from one used for vaccination. Data on such alternative schedules are scarce. This prospective...
<p>Supplementary Figure 6: Correlation between CD4+ and CD8+ T cell responses SARS-CoV-2 binding antibodies post homologous or heterologous booster vaccination in cancer patients.</p>
<p>Supplementary Figure 6: Correlation between CD4+ and CD8+ T cell responses SARS-CoV-2 binding antibodies post homologous or heterologous booster vaccination in cancer patients.</p>
<p>Supplementary Figure 4: Spike-specific CD4+ T cell responses post homologous or heterologous booster vaccination in subcohorts.</p>
<p>Supplementary Figure 3: Gating strategy for a representative sample</p>
<p>Supplementary Figure 3: Gating strategy for a representative sample</p>
<p>Supplementary Figure 1: Correlation betweenSARS-CoV-2 anti-S1 IgG antibody titers and NT50 values against Wuhan BA.1 Omicron strains post homologous or heterologous booster vaccination in cancer patients healthy individuals.</p>
<p>Supplementary Figure 2: Virus neutralization test with 50% titers (NT50) defined as the sample dilution (reciprocal titer) conveying in SARS-CoV-2 (strains 2019-nCoV-Italy-INMI1 and VLD20211207) infected wells.</p>
<p>Supplementary Figure 5: Spike-specific CD8+ T cell responses post homologous or heterologous booster vaccination in subcohorts.</p>
<p>Supplementary Figure 2: Virus neutralization test with 50% titers (NT50) defined as the sample dilution (reciprocal titer) conveying in SARS-CoV-2 (strains 2019-nCoV-Italy-INMI1 and VLD20211207) infected wells.</p>
<p>Supplementary Figure 5: Spike-specific CD8+ T cell responses post homologous or heterologous booster vaccination in subcohorts.</p>
<p>Supplementary Figure 4: Spike-specific CD4+ T cell responses post homologous or heterologous booster vaccination in subcohorts.</p>
<p>Supplementary Figure 1: Correlation betweenSARS-CoV-2 anti-S1 IgG antibody titers and NT50 values against Wuhan BA.1 Omicron strains post homologous or heterologous booster vaccination in cancer patients healthy individuals.</p>